XPRIZE Healthspan is a seven-year competition designed to push aging research beyond incremental improvements. Participating teams are developing and testing interventions intended to restore muscle, cognitive, and immune performance in adults between 50 and 90 years of age. The competition defines success as producing measurable improvements equivalent to at least 10 years of healthier function—and potentially as much as 20 years—within one year or less of treatment. The goal is not simply to increase lifespan, but to delay or reverse functional decline while people remain active and independent.

The NYC-Vita team is conducting a clinical trial that combines lifestyle and pharmaceutical interventions to examine whether immune-system performance can be improved during aging. The study reflects a growing scientific consensus that aging is not governed by a single mechanism. Instead, it emerges from interconnected changes involving chronic inflammation, metabolic dysfunction, impaired tissue repair, altered immune-cell behavior, vascular damage, and declining neurological resilience. By measuring these processes together, the researchers hope to determine whether targeted interventions can produce broad improvements in healthspan rather than isolated changes in one organ.

A central scientific focus of the program is the aging immune system, a process known as immunosenescence. With age, immune cells may become less responsive to new infections and vaccines, while other immune populations can remain persistently activated and promote low-grade inflammation. This chronic inflammatory state, sometimes called inflammaging, has been associated with cardiovascular disease, neurodegeneration, frailty, metabolic disorders, and reduced ability to recover from illness. NYC-Vita is designed to investigate whether pharmaceutical and behavioral strategies can shift the immune system toward a more balanced and effective state.

The Mount Sinai effort brings together specialists in immunology, neuroscience, metabolism, medical imaging, wearable technology, and clinical investigation. Miriam Merad, MD, PhD, leads the NYC-Vita team and is internationally recognized for her research on macrophages, immune cells that regulate inflammation, tissue repair, and responses to disease. The team also includes Zahi Fayad, PhD, whose work uses advanced imaging and wearable technologies to study biological and lifestyle stressors; Fanny Elahi, MD, PhD, an expert in neurodegeneration and brain health; Thomas Marron, MD, PhD, principal investigator of the NYC-Vita clinical trial; and Ryan W. Walker, PhD, MS, whose research examines metabolic and nutritional influences on healthy aging.

For the study, the researchers are expected to evaluate healthspan using multiple biological and functional measures rather than relying on chronological age alone. Such assessments can include immune-cell profiles, inflammatory markers, metabolic measurements, neurocognitive testing, physical-performance data, and imaging-based indicators of tissue health. Wearable devices may provide continuous information about activity, sleep, heart-rate patterns, and other behavioral signals. Combining these data streams could help researchers identify whether an intervention produces a coordinated improvement across systems or merely changes a laboratory measurement without meaningful benefits in daily life.

“Advancing to the finals of this highly competitive global initiative reflects the exceptional scientific foundation we have built at Mount Sinai and the strength of our collaborative research enterprise,” said Eric J. Nestler, MD, PhD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai and Executive Vice President of the Mount Sinai Health System. He said the collaboration across immunology, neuroscience, metabolism, imaging, and clinical research could help redefine how healthy aging is understood and promoted.

Merad said the team’s selection as a finalist recognizes both the promise of its scientific strategy and the work of its multidisciplinary researchers. The $1 million award will support the continued development of NYC-Vita and help accelerate investigations into interventions that may preserve physical strength, independence, and quality of life. The program is part of Mount Sinai’s broader Healthspan Program, which links biomedical research with clinical care and aims to translate discoveries about aging into practical approaches for preventing or delaying age-related disease.

XPRIZE announced 20 finalist teams at an awards ceremony in Salt Lake City. Ten of those teams, including Mount Sinai, were selected as Milestone 2 Awardees and will share $10 million in direct milestone funding, with each receiving $1 million. Awardees will also gain access to clinical testing resources intended to speed the evaluation of their therapeutic approaches. The finalists represent the United States, South Korea, Japan, and China, underscoring the international competition surrounding efforts to alter the biology of aging. The contest is scheduled to culminate in 2030, when XPRIZE plans to award a grand prize of up to $81 million. Mount Sinai leaders said the team will continue the NYC-Vita trial while seeking additional collaborators and philanthropic support to expand the research and determine whether improvements in immune health can translate into longer, healthier lives.

Subject of Research: Healthy aging, immune-system function, immunosenescence, inflammaging, and interventions designed to extend healthspan.

Article Title: Mount Sinai Team Advances to XPRIZE Healthspan Finals With Immune-Aging Clinical Trial

News Publication Date: August 11, 2026

Web References:
https://www.mountsinai.org/about/healthspan/research
https://profiles.mountsinai.org/miriam-merad
https://profiles.mountsinai.org/zahi-a-fayad
https://profiles.mountsinai.org/fanny-m-elahi
https://profiles.mountsinai.org/thomas-u-marron
https://profiles.icahn.mssm.edu/ryan-w-walker
https://www.mountsinai.org/about/executive-leadership/nestler
https://www.mountsinai.org/about/executive-leadership/brendan-carr

References: XPRIZE Healthspan competition announcement; Icahn School of Medicine at Mount Sinai NYC-Vita clinical trial and Healthspan Program information.

Keywords: healthy aging, healthspan, XPRIZE Healthspan, NYC-Vita, immune aging, immunosenescence, inflammaging, macrophages, clinical trial, Mount Sinai, longevity research, age-related disease, medical imaging, wearable technology, neuroscience, metabolism

The concept builds on the increasingly influential idea of “Medicine 3.0,” which emphasizes disease prevention, personalized care, early risk detection, and the extension of healthspan—the period of life spent in good health. Medicine 4.0 retains those goals but adds a third dimension to the traditional focus on lifespan and healthspan: access. In Macdonald’s framework, a healthcare system cannot be considered fully advanced if its most effective interventions are available only to people with the financial, geographic, or social resources to obtain them.

The proposed model treats access as more than the ability to visit a doctor or purchase a medicine. It includes access to preventive screening, essential treatments, reliable health information, clinical trials, and the infrastructure required to deliver care. It also includes access to scientific inquiry itself. According to the commentary, potentially important research questions can be delayed or neglected when regulatory systems, funding priorities, political pressures, cultural assumptions, or commercial interests determine which areas of science are considered acceptable or profitable.

This distinction is technically important because modern healthcare increasingly depends on prevention rather than treatment after disease has developed. Vaccination, blood-pressure control, cancer screening, lipid reduction, nutritional interventions, and early detection can reduce disease risk long before symptoms appear. Yet the effectiveness of these measures at the population level depends on coverage. A highly effective intervention can have limited public-health impact if it reaches only a small, affluent segment of society. In epidemiological terms, the benefit of an intervention is shaped not only by its individual efficacy but also by its distribution across the population.

The commentary points to persistent differences in access between and within countries. In wealthier nations, advanced preventive medicine may be linked to private healthcare, specialist services, expensive insurance plans, or subscription-based programs. In lower-income regions, barriers may involve shortages of essential medicines, inadequate primary-care facilities, limited vaccination infrastructure, unreliable transport, and a lack of clean water. These conditions can prevent communities from benefiting from advances that are already scientifically established, making innovation alone insufficient to improve global health.

Macdonald also argues that scientific research requires a form of access that is often overlooked. The paper discusses the history of psychedelic research as an example of how external forces can shape the scientific agenda. For decades, regulatory restrictions, political responses, and cultural stigma limited clinical investigation of psychedelic compounds. Renewed research has since examined their possible use in conditions including post-traumatic stress disorder, depression, alcohol use disorder, and anxiety associated with terminal illness. The example does not establish that these treatments are universally safe or effective; rather, it illustrates the importance of allowing carefully controlled studies to test controversial hypotheses.

In clinical science, such openness must be balanced by rigorous safeguards. New interventions require laboratory research, dose-finding studies, randomized clinical trials, long-term monitoring, and evaluation of adverse effects before they can be incorporated into routine care. Macdonald’s argument is not that every unconventional idea should be adopted, but that scientific questions should be assessed through evidence rather than rejected solely because they conflict with prevailing political, cultural, or commercial expectations. Removing unnecessary barriers to investigation can increase the chance that useful therapies are identified, while scientific standards determine whether those therapies should be used.

The paper further examines the role of financial incentives in shaping healthcare priorities. Healthcare systems often reward activities that generate immediate revenue, such as procedures, consultations, and long-term treatment, while providing weaker incentives for prevention or interventions whose benefits may appear years later. This creates a structural problem: the economic value of preventing a disease may be distributed across society and realized in the future, whereas the costs of prevention are frequently immediate and concentrated. Medicine 4.0 therefore calls for payment and policy systems that reward measurable improvements in population health, rather than focusing primarily on the volume of services delivered.

Digital health and artificial intelligence could either strengthen or undermine this goal. Smartphone applications, wearable sensors, remote monitoring, automated risk assessment, and machine-learning systems can make some forms of preventive care more scalable. Algorithms can identify patterns in physiological data, support earlier warnings, and help clinicians manage large populations. However, these technologies require access to devices, internet connectivity, technical support, and trustworthy data governance. If health platforms depend on costly subscriptions, paywalls, or advertising models that exploit personal information, they could deepen existing inequalities instead of democratizing care.

The Medicine 4.0 framework ultimately presents access as a scientific and ethical requirement rather than an optional social benefit. Inspired in part by Francis Bacon’s view of science as a means of improving the human condition, the commentary argues that medical progress should be judged by both the sophistication of new discoveries and the breadth of their reach. A healthcare system that combines prevention, personalized risk management, open inquiry, and equitable distribution, Macdonald suggests, would be better positioned to convert scientific progress into longer and healthier lives for the whole population.

Subject of Research: People

Article Title: “Medicine 4.0: the era of revolutionary access”

Web References: https://doi.org/10.3389/fmed.2026.1903811

Keywords

Medicine 4.0, healthcare access, preventive medicine, healthspan, personalized medicine, public health, medical research, scientific inquiry, digital health, artificial intelligence, health inequality, healthcare policy

The essence of Cell Annealing builds on the metaphor of annealing—a process widely used in metallurgy where controlled heating and cooling cycles are applied to metals to refine their internal structure and enhance their physical properties. By applying an analogous conceptual framework to living cells, the researchers hypothesize that intermittent and controlled “thermal-like” or stress-related perturbations can induce cells to reconfigure their damaged biomolecules and subcellular structures, effectively “repairing” accumulated molecular lesions that are central to aging. The model provides a robust phenomenological description of how these annealing cycles could alleviate subcellular entropy and restore functions eroded by chronological and replicative aging.

A key insight from Memczak and colleagues is their integration of biological complexity with thermodynamic principles. Aging is traditionally viewed as a decline in cellular robustness due to the accumulation of damage in DNA, proteins, lipids, and organelles. Their Cell Annealing model reframes this process as one susceptible not only to inevitable degradation but also to cyclical restoration. Controlled perturbations, similar to thermal inputs in metallurgical annealing, prompt cellular quality control mechanisms such as proteostasis networks, DNA repair pathways, and autophagic clearance to enter heightened states of activity. These cyclical activations allow the cells to “prune” away dysfunctional components, promote molecular chaperoning, and rebalance metabolic flux—all of which contribute to sustained cellular functionality.

This phenomenological approach offers several advantages. Unlike genetic manipulations or pharmacological interventions that often target singular pathways, Cell Annealing encompasses a holistic cellular rewriting. The model’s predictive power lies in its ability to reconcile disparate age-related molecular pathways within a unifying physical paradigm. It leverages known cellular stress responses including hormesis—a process where mild stress enhances resilience—to propose a systemic cycling that yields net restorative effects rather than cumulative damage.

The experimental evidence supporting this model was gathered by mimicking annealing cycles in cultured human cells using controlled pulses of mild oxidative stress and transient metabolic inhibition. These perturbations were carefully tuned to avoid permanent damage but sufficient to trigger endogenous repair machinery. Over repeated cycles, cells demonstrated improved mitochondrial function, enhanced DNA repair kinetics, and reduced senescence markers. Intriguingly, single-cell transcriptomic analyses showed a temporal resetting of age-associated gene expression profiles toward a more youthful state after the annealing regimen.

At a molecular level, this restoration appears to be coordinated by oscillations in key signaling nodes such as AMPK, mTOR, and sirtuins, themselves known central regulators of aging and metabolism. The model also underscores the importance of phase separation dynamics—the process by which cells compartmentalize biochemical reactions in membraneless organelles—in mediating the reorganizational events during annealing. By modulating the material states of these condensates, cells dynamically facilitate the segregation and elimination of damaged components.

Beyond cultured cells, the authors speculate that Cell Annealing could be promoted in vivo by carefully orchestrated interventions such as intermittent fasting, hypoxic conditioning, or controlled thermal therapies. These approaches have been independently associated with anti-aging effects, but the new model provides a mechanistic rationale tying their benefits to cyclical annealing-like cellular reprogramming. If realized therapeutically, such dynamic treatments would mark a paradigm shift, moving aging interventions away from static maintenance and toward actively induced rejuvenation cycles.

Importantly, Memczak et al. emphasize that while Cell Annealing departs from purely genetic or pharmacological anti-aging solutions, it remains compatible with them. This suggests a future where combined approaches, layering annealing cycles with precision senolytics, epigenetic modulators, or gene therapies, may synergize to achieve unparalleled gains in healthspan and lifespan extension. It also raises profound questions about the limits of biological plasticity and whether such cyclical restoration can ultimately overcome species-specific aging clocks.

Confronting the intrinsic heterogeneity within tissues and cell populations remains a challenge for practical deployment. The model accounts for this complexity by proposing that the timing, magnitude, and frequency of annealing cycles must be fine-tuned to each cell type’s bioenergetic and stress response profile. For example, stem cells may require different protocols than differentiated somatic cells to maximize rejuvenative outcomes while minimizing oncogenic risks. Understanding these parameters will require interdisciplinary efforts spanning systems biology, physics, and clinical sciences.

Notably, the Cell Annealing framework also intersects with emerging fields such as systems gerontology and bioinformatics. Integrating multi-omics data with predictive computational models enables the mapping of aging trajectories at individual and population levels. This marriage of data science and phenomenology enhances the capacity to simulate potential annealing protocols before in vivo testing, accelerating translational timelines.

Science enthusiasts and the general public alike are captivated by the tantalizing possibility that aging could be turned from a one-way descent into a reversible cycle. However, the authors caution that application in humans necessitates rigorous validation, particularly around safety and long-term effects. While early results are promising, biological systems are enormously complex, and the risk of unintended consequences such as dysregulated cell proliferation or immune dysfunction must be carefully managed.

This conceptual breakthrough resonates with broader philosophical shifts in aging research—from perceiving aging as an inexorable decline to recognizing it as an amenable process where cellular plasticity can be harnessed. Cell Annealing offers a fresh lens through which to view longevity, where time itself becomes a malleable parameter controlled through intelligent modulation of cellular states.

Furthermore, the implications of this model extend into regenerative medicine and chronic disease management. Aging is the principal risk factor for neurodegenerative diseases, cardiovascular pathologies, and cancer. By reshaping the cellular milieu toward youthful functional states, annealing may open avenues for disease prevention and improved recovery from injury, potentially transforming the healthcare landscape.

As the field moves forward, experimentalists will seek to refine the molecular triggers and mechanical forces that underlie annealing cycles, while clinical researchers will explore minimally invasive methods to induce analogous states in patients. Interdisciplinary collaboration will be essential, merging insights from physics, molecular biology, computational modeling, and clinical expertise to realize the full potential of cell annealing as a longevity modality.

In sum, the Cell Annealing model proposed by Memczak and colleagues marks a visionary stride in aging biology, blending theoretical elegance with empirical promise. It challenges long-standing dogmas and offers a roadmap to one day escape the frailty of aging through orchestrated cellular rejuvenation. While challenges persist, the horizon of biomedicine is now illuminated by this innovative concept, inspiring hope that aging may no longer be an immutable fate but a challenge to be met with science and ingenuity.

Subject of Research: Cellular aging and rejuvenation through the phenomenological model of Cell Annealing.

Article Title: Escaping ageing through Cell Annealing—a phenomenological model.

Article References:
Memczak, S., Izpisua Belmonte, J.C. & Graepel, T. Escaping ageing through Cell Annealing—a phenomenological model. Cell Res 35, 535–538 (2025). https://doi.org/10.1038/s41422-025-01138-z

Image Credits: AI Generated

Gerophysics represents a promising interdisciplinary field that borrows heavily from theoretical physics to address the complexities of biological aging. Historically, the application of physics has revolutionized numerous industries—from finance to artificial intelligence—reshaping our understanding of both the material world and life itself. Now, researchers are pivoting to a less conventional application of these methodologies, targeting the fundamental mechanisms that drive aging. By leveraging theoretical constructs such as statistical mechanics and complex systems theory, there lies a tantalizing potential to decode the biological enigma of aging.

The conference will be a melting pot for scholars and researchers hailing from diverse scientific backgrounds, all uniting under a common purpose. Participants will engage in discussions not only about the physics of aging but also about the biological systems involved. The synergy created by this collaborative atmosphere could lead to revolutionary breakthroughs that reshape contemporary understandings of longevity. In this light, gerophysics is positioned as a venue for intellectual exchanges that stoke creativity and innovation—a true scientific convergence.

One cornerstone of the conference is the development of a shared scientific language and toolkit for conducting aging research. Researchers often work within narrow disciplines, employing terminology and methodologies that can be at odds with those of their peers. Establishing a standardized lexicon can facilitate collaboration, making it easier for scientists from different fields to communicate effectively and work together to address common objectives. This shared language may also expedite the process of innovation, as new ideas can spread more seamlessly across disciplines.

In addition to linguistic cohesion, the conference opens doors for exploration into novel experimental frameworks. Traditional approaches to studying aging have largely focused on biological pathways and molecular mechanisms. However, viewing these processes through the lens of physics allows for the incorporation of dynamical modeling and statistical methods, which could yield fresh insights into the aging process. For example, understanding aging as a complex system influenced by various factors could shift the focus from mere characterization of cellular pathways to a broader investigation that includes environmental and lifestyle variables.

Furthermore, fostering collaborations at the conference could have far-reaching implications for extending healthy lifespans. Aging research stands at a crossroads, with many potential avenues to explore. The complexity of biological aging necessitates an integrated approach, one that breaks free from siloed thinking. By facilitating connections among diverse stakeholders, ranging from physicists and biologists to clinical researchers and public health experts, the conference aims to catalyze multi-disciplinary projects that could expedite the translation of scientific discoveries into practical applications.

What makes gerophysics particularly appealing is its foundation in collaboration. By inviting scientists and thought leaders from various specialties, the conference aims to serve as a cross-pollination ground where ideas can flourish unbounded by traditional disciplinary constraints. When physicists, biologists, and gerontologists come together, they bring unique perspectives that can enrich the dialogue surrounding aging and healthspan. The value of this collaboration cannot be understated; collectivizing expertise could lead to fresh methodologies and innovative solutions to some of the most pressing challenges in aging research.

In the global landscape where aging-related diseases like Alzheimer’s and various forms of cancer are on the rise, addressing the factors contributing to biological aging has never been more urgent. The intersection of gerophysics and aging biology could illuminate the pathways involved in the onset and progression of these diseases. The holistic approach proposed at the conference seeks not just to extend lifespans but to enhance the quality of life as we age, laying the groundwork for a healthier population in the years to come.

As we await the advent of this groundbreaking conference, interest is surging within the scientific community. Being recognized as a media partner, Aging (Aging-US) is poised to amplify the significance of the event and its outcomes. The journal’s commitment to disseminating insights from the conference reflects a deeper purpose: to ensure that findings reach a broad audience, fostering advancements in the understanding of aging worldwide.

To stay engaged with the themes of the conference, scientists and enthusiasts can follow updates via social media platforms like LinkedIn and X (formerly Twitter). These channels will serve as conduits, enabling the broader community to remain connected with ongoing discussions, emerging research, and future initiatives emanating from the convergence of physics and gerontology.

As the concept of gerophysics continues to unfold, its implications extend beyond academia. It holds the potential to inform public health policies and educational initiatives aimed at promoting healthy aging. The ideas and collaborations birthed at the Global Conference on Gerophysics may well lead to a new standard of care and understanding regarding age-related diseases—a significant leap towards a future where aging is not merely endured, but embraced as a natural part of the human experience.

With such promising avenues for exploration and collaboration on the horizon, the Global Conference on Gerophysics positions itself as a beacon of hope in the quest for longevity. As experts gather to chart new territories in the intersection of physics and biology, the collective efforts could illuminate pathways to healthier, longer lives, paving the way for groundbreaking advancements in the study of aging.

This vase of potential spells excitement for researchers, institutions, and ultimately, for society at large. The dedication to seeking interdisciplinary solutions in the often-complex field of aging could redefine not only how we perceive the biological aging process but also how we address the profound challenges that accompany it.

Subject of Research: Gerophysics – The Intersection of Physics and Aging Biology
Article Title: The Convergence of Physics and Aging: A New Era in Gerophysics
News Publication Date: January 21, 2025
Web References: Aging (Aging-US), Global Conference on Gerophysics
References: N/A
Image Credits: National University of Singapore (NUS) Yong Loo Lin School of Medicine

Keywords

Aging, Gerophysics, Longevity, Research, Conference, Physics, Biology, Collaboration, Healthspan, Lifespan, Interdisciplinary Science, Aging Research